Celltrion Named Preferred Bidder for U.S. Pharma Facility to Mitigate Tariff Exposure
Seoul, South Korea – July 29, 2025South Korean biopharmaceutical company Celltrion announced Tuesday that it has been selected as the preferred bidder to acquire a U.S.-based pharmaceutical manufacturing facility from an undisclosed global firm. The move is part of Celltrion’s strategy to mitigate potential risks associated with proposed U.S. tariffs on pharmaceutical imports. Founder and […]
Continue Reading